Sep 20, 2023 / 03:00PM GMT
Alex Thompson - Stifel, Nicolaus & Company, Inc. - Analyst
Great. Good morning, everyone. We're back again. We have Cameron Turtle, COO of Aeglea BioTherapeutics here with us for a fireside chat. I'm going to turn it over to Cameron now to give a brief overview of Spyre, and then we'll get into the Q&A.
Cameron Turtle - Aeglea BioTherapeutics, Inc. - COO
Sounds good. Thanks, Alex, and thanks, everyone, for taking the time this morning. So our ambition with Spyre is pretty straightforward, which is to develop a next generation of IBD therapies that we think can provide a step change in the convenience and efficacy of therapies compared to what's currently available as standard of care.
And in particular, we're aiming to do this with really three strategic pillars here, which is, first, making extended half-life, high-concentration antibodies against what we think are the best targets in IBD, which are alpha 4, beta 7, TL1A, and IL-23, the first two of which we expect our programs to go into the clinic next year. And common to all of these
Aeglea Bio Therapeutics Inc at Stifel Immunology and Inflammation Virtual Summit Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers